Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633723 | 0.94 | MAPT (0.44) | TACR1MMP2MMP9P2RY14MEN1 | |
| SCHEMBL4633706 | 0.94 | TACR1 (0.44) | TACR1MMP2MMP9P2RY14MEN1 | |
| SCHEMBL14161919 | 0.94 | TACR1 (0.44) | TACR1MMP2MMP9P2RY14MEN1 | |
| SCHEMBL4634227 | 0.93 | TACR1 (0.44) | TACR1MMP2MMP9MEN1KMT2A | |
| SCHEMBL13945806 | 0.93 | MMP9 (0.47) | MMP2MMP9P2RY14MEN1KMT2A | |
| SCHEMBL14161994 | 0.92 | ITGB2 (0.45) | TACR1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4632692 | 0.92 | ITGB2 (0.44) | MEN1KMT2AMAPTTHRBSMN1; SMN2 | |
| SCHEMBL4632740 | 0.92 | ITGB2 (0.46) | TACR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL4737003 | 0.92 | KMT2A (0.49) | TACR1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4633411 | 0.91 | HDAC3 (0.43) | TACR1MMP2MMP9P2RY14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1932831-A1 | 1,2-Diarylacetylene Derivatives of Acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | claimed |
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008071453-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1932831-A1 | 1,2-Diarylacetylene Derivatives of Acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | TACR1 179/4885MMP2 4314/4885MMP9 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.